PANalytical becomes distributor for OBLF product line
Underlining relationship between the two companies, PANalytical and OBLF jointly announce that a formal agreement has been signed for the distribution of OBLF’s optical emission spectrometers by PANalytical in Finland, Sweden, Norway, Denmark, the Netherlands, Belgium, Luxemburg, United Kingdom, Ireland, France, Spain, Portugal, Italy, South Africa, USA, Canada and Brazil.
PANalytical X-ray fluorescence (XRF) spectrometers and OBLF optical emission spectrometers (OES) perform complementary roles in the analysis of solid metals. When deployed together, XRF and OES allow for the measurement of elements over concentration ranges from sub-ppm to 100% within seconds. This combination of speed and versatility makes XRF and OES ideal for laboratories where metals analysis is a primary task.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
UF discovery could lead to better genetic screening for diabetes

Unpacking asymmetric cell division

The carotenoid transfer between 2 proteins

Wacker Biotech B.V. - Amsterdam, Netherlands

Spices and herbs: Ingredients which may pose a health risk

A peptide against cannibalism - A small molecule safeguards roundworm larvae against parental attacks
The_Fertility_Society_of_Australia

Cells that sense light without seeing
Discovery opens door to therapeutic development for FSH muscular dystrophy
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for Vitreomacular Adhesion - Highly significant trial result (p=0.003) demonstrates the potential of microplasmin in the treatment of retinal disease

Combination Pack Battles Cancer - Nanoparticles with multifunctional drug precursor for synergistic tumor therapy
